Hugely popular weight loss drugs known as GLP-1's are finally getting cheaper, well at least one is, and that's the case with ...
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...
Following the results of a study by USC Annenberg Inclusion Initiative demonstrating the lack of adequate representation of ...
Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...
Eli Lilly now offers higher doses of its weight-loss drug Zepbound in vial form at a discount to the injector pen versions.
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...
Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback